drugset / Trial / NCT06812871
High-dose Furmonertinib Combined With Bevacizumab and Intrathecal Pemetrexed Chemotherapy in Patients With EGFR-mutated Non-small Cell Lung Cancer and Meningeal Metastasis
NaSingle-groupOpen-labelTreatment
Summary
the study conducted to evaluate the efficacy and safety of high-dose furmonertinib (160 mg qd) combined with bevacizumab and pemetrexed intrathecal chemotherapy in NSCLC patients with EGFR mutations and meningeal metastases.
Timeline
- Start
- 2024-01-01
- Primary completion
- 2025-10-20
- Completion
- 2026-03-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bevacizumab | Monoclonal antibody | 7.5 mg/kg | — |
| Subject | Firmonertinib | Small molecule | 160 mg | — |
| Subject | Pemetrexed | Small molecule | 50 mg | Intrathecal |